Exabis Library
Welcome to the e-CCO Library!
P531: Tuberculin skin test conversion rate in inflammatory bowel disease patients receiving anti-TNFα agents
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P532 Measuring endoscopic activity in patients treated with vedolizumab for ulcerative colitis
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P532: 1-Year Clinical Outcome of Subcutaneous Infliximab compared with Intravenous Infliximab in Patients with Inflammatory Bowel Disease During Maintenance Therapy
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P532: Biosimilar infliximab in anti-TNF naive inflammatory bowel disease patients – one-year clinical follow-up
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P532: Delay of maintenance infliximab increases the risk of relapse in Crohn’s disease during the COVID-19 pandemic
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P532: Efficacy of combination therapy with cyclosporin and vedolizumab in inflammatory bowel diseases refractory to anti-TNF agents
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P532: Proactive therapeutic drug monitoring improves clinical outcomes in patients with inadequate post-induction infliximab trough levels
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P532: Safety and efficacy of endoscopic dilation of small bowel Crohn’s disease strictures by balloon-assisted enteroscopy: pooled analysis of individual data from 210 patients
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P533 Long-term quality of life after minimally invasive surgery for Crohn’s disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P533: Adalimumab 80mg every other week in inflammatory bowel disease: Treatment intensification outcomes in real life clinical practice
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P533: Anaemia and iron deficiency in gastroenterology: a Scandinavian prospective, observational study of iron isomaltoside in clinical practice
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P533: Correlation of endoscopic and clinical endpoints during induction therapy in patients with moderate-to-severe Crohn’s disease: Analysis from CELEST study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P533: Predictors of sustained remission after infliximab de-escalation in patients with inflammatory bowel diseases
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P533: Relation between TL1A expression in intestinal mucosa, and endoscopic severity and clinical course in ulcerative colitis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P533: Ustekinumab therapeutic drug monitoring in Crohn’s disease patients with loss of response
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P534 Qualitative perspectives of parent and child participants from a trial of faecal microbiota transplant for paediatric ulcerative colitis
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P534: Dual biologic or small molecules therapy in refractory paediatric inflammatory bowel disease (DOUBLE-PIBD): A multi-center study from the paediatric IBD Porto group of ESPGHAN
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P534: Effectiveness and safety of Adalimumab switch from originator to biosimilar in patients with inflammatory bowel disease in clinical remission
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P534: IBD-related malignancies observed in 2015–2018: 4 years’ results from the prospective nationwide Hungarian registry
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P534: Illness perception in IBD patients: a prospective study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM